Pfizer buys Amplyx to expand drug-resistant treatment portfolio
29 April 2021
Pfizer Inc said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant “superbug” fungal infections in patients with compromised immune systems.
If approved, Amplyx’s lead drug fosmanogepix would be the first new class of antifungal treatments in 20 years. Terms of the deal were not disclosed.
Fungi, like bacteria, can develop the ability to defeat the drugs designed to kill them.
Further reading: WHTC
Author(s): Julie Steenhuysen
Healthy Patients Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
